ISRG · NMS · Healthcare
Intuitive Surgical, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 104.37
Market price
USD 393.33
Implied upside
-73.5%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 37.3x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 11.8bn | USD 13.9bn | USD 16.3bn | USD 19.1bn | USD 22.4bn | +17.4% |
| EBIT | USD 3.2bn | USD 3.7bn | USD 4.4bn | USD 5.1bn | USD 6.0bn | +17.4% |
| NOPAT | USD 2.8bn | USD 3.2bn | USD 3.8bn | USD 4.5bn | USD 5.3bn | +17.4% |
| Add depreciation & amortisation | USD 737.6m | USD 865.9m | USD 1.0bn | USD 1.2bn | USD 1.4bn | +17.4% |
| Less capital expenditure | USD -1.2bn | USD -1.5bn | USD -1.7bn | USD -2.0bn | USD -2.4bn | +17.4% |
| Less increase in working capital | USD -1.3bn | USD -1.5bn | USD -1.8bn | USD -2.1bn | USD -2.5bn | +17.4% |
| Free cashflow to firm | USD 950.2m | USD 1.1bn | USD 1.3bn | USD 1.5bn | USD 1.8bn | +17.4% |
| Discount factor | 0.9440 | 0.8413 | 0.7497 | 0.6681 | 0.5954 | - |
| Present value | USD 897.0m | USD 938.4m | USD 981.7m | USD 1.0bn | USD 1.1bn | +4.6% |
| Present Value Of The Forecast | USD 4.9bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.312 | Reported 1.465, pulled toward 1.0 (Blume) |
| Cost of equity | 12.21% | Risk-free + beta x equity risk premium |
| Cost of debt | 7.00% | Assumed: risk-free + 2bp (interest expense not reported) |
| Market capitalisation | USD 140.9bn | 100.0% of capital |
| Total debt | USD 0.00 | 0.0% of capital, book value as a proxy |
| Tax rate | 12.9% | Effective, capped at statutory |
| WACC | 12.21% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
85% of EV
- Forecast FCFF, final year
- USD 1.8bn
- Capex at depreciation, working capital in reinvestment
- USD 5.4bn
- Less reinvestment at g/ROIC (20.1% of NOPAT)
- USD -1.1bn
- Capitalised
- USD 4.3bn
- ROIC (reported)
- 12.5%
- Terminal value, undiscounted
- USD 45.4bn
- Terminal value, discounted
- USD 27.0bn
- Enterprise value
- USD 31.9bn
- Less net debt
- USD -5.9bn
- Equity value
- USD 37.9bn
Exit at 20.0x EBITDA
95% of EV
- Terminal value, undiscounted
- USD 148.6bn
- Terminal value, discounted
- USD 88.5bn
- Enterprise value
- USD 93.4bn
- Less net debt
- USD -5.9bn
- Equity value
- USD 99.4bn
Spread between methods: 90%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 10.21% | 128.64 | 130.36 | 132.24 | 134.33 | 136.67 |
| 11.21% | 114.71 | 115.65 | 116.65 | 117.73 | 118.90 |
| 12.21% | 103.48 | 103.92 | 104.37 | 104.84 | 105.31 |
| 13.21% | 94.77 | 95.09 | 95.41 | 95.73 | 96.05 |
| 14.21% | 87.54 | 87.83 | 88.11 | 88.40 | 88.69 |
Outlined: this model. Green text: above today's price of 393.33. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 17.4% | 67.5% | +50.1pp |
| Discount rate | 12.2% | 5.2% | -7.0pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.